Aravive Inc (ARAV) Fundamental Analysis & Valuation
NASDAQ:ARAV • US03890D1081
Current stock price
0.0401 USD
-0.01 (-13.39%)
At close:
0.042 USD
+0 (+4.74%)
After Hours:
This ARAV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ARAV Profitability Analysis
1.1 Basic Checks
- In the past year ARAV has reported negative net income.
- In the past year ARAV has reported a negative cash flow from operations.
1.2 Ratios
- ARAV has a worse Return On Assets (-306.54%) than 96.29% of its industry peers.
- ARAV's Return On Equity of -2344.12% is on the low side compared to the rest of the industry. ARAV is outperformed by 86.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| ROIC | N/A |
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ARAV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ARAV Health Analysis
2.1 Basic Checks
- ARAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ARAV has more shares outstanding
- There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -81.87, we must say that ARAV is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -81.87, ARAV is not doing good in the industry: 98.99% of the companies in the same industry are doing better.
- There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -81.87 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
- A Current Ratio of 0.98 indicates that ARAV may have some problems paying its short term obligations.
- The Current ratio of ARAV (0.98) is worse than 90.56% of its industry peers.
- ARAV has a Quick Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
- ARAV has a worse Quick ratio (0.98) than 89.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 |
3. ARAV Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 59.32% over the past year.
- The Revenue for ARAV has decreased by -19.28% in the past year. This is quite bad
- ARAV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.56% yearly.
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%
3.2 Future
- The Earnings Per Share is expected to grow by 10.50% on average over the next years. This is quite good.
- ARAV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -21.62% yearly.
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. ARAV Valuation Analysis
4.1 Price/Earnings Ratio
- ARAV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year ARAV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ARAV's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y25.99%
5. ARAV Dividend Analysis
5.1 Amount
- No dividends for ARAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARAV Fundamentals: All Metrics, Ratios and Statistics
0.0401
-0.01 (-13.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)03-13 2024-03-13/amc
Inst Owners0.01%
Inst Owner Change0.27%
Ins Owners5.52%
Ins Owner Change0%
Market Cap2.95M
Revenue(TTM)6.99M
Net Income(TTM)-39.85M
Analysts43.33
Price Target0.26 (548.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)210.2%
Min EPS beat(2)58.96%
Max EPS beat(2)361.44%
EPS beat(4)2
Avg EPS beat(4)66.57%
Min EPS beat(4)-103.8%
Max EPS beat(4)361.44%
EPS beat(8)3
Avg EPS beat(8)34.04%
EPS beat(12)6
Avg EPS beat(12)27.35%
EPS beat(16)8
Avg EPS beat(16)14.94%
Revenue beat(2)2
Avg Revenue beat(2)584.84%
Min Revenue beat(2)187.33%
Max Revenue beat(2)982.35%
Revenue beat(4)4
Avg Revenue beat(4)384.65%
Min Revenue beat(4)125.18%
Max Revenue beat(4)982.35%
Revenue beat(8)7
Avg Revenue beat(8)250.15%
Revenue beat(12)10
Avg Revenue beat(12)281.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)67.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.74 | ||
| P/tB | 1.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.96
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | -81.87 |
F-Score3
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154.9%
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Sales Q2Q%-44.35%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%
EBIT growth 1Y8.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.95%
EBIT Next 3Y2.34%
EBIT Next 5Y-6.26%
FCF growth 1Y-203.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-203.21%
OCF growth 3YN/A
OCF growth 5YN/A
Aravive Inc / ARAV Fundamental Analysis FAQ
What is the ChartMill fundamental rating of Aravive Inc (ARAV) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ARAV.
Can you provide the valuation status for Aravive Inc?
ChartMill assigns a valuation rating of 1 / 10 to Aravive Inc (ARAV). This can be considered as Overvalued.
What is the profitability of ARAV stock?
Aravive Inc (ARAV) has a profitability rating of 0 / 10.